Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 7/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3665172 | 0.94 | MAPK14 (0.49) | MAPK14MAPK13ABL1BRAFFGFR1 | |
| SCHEMBL3634875 | 0.89 | MAPK14 (0.68) | MAPK14MAPK13ABL1BRAFFGFR1 | |
| SCHEMBL3798969 | 0.86 | MAPK14 (0.57) | MAPK14MAPK13ABL1BRAFFGFR1 | |
| SCHEMBL3802294 | 0.86 | MAPK14 (0.59) | MAPK14MAPK13ABL1BRAFFGFR1 | |
| SCHEMBL3666268 | 0.85 | MAPK14 (0.61) | MAPK14MAPK13ABL1BRAF | |
| SCHEMBL5065426 | 0.84 | MAPK14 (0.57) | MAPK14MAPK13ABL1BRAFFGFR1 | |
| SCHEMBL3808549 | 0.83 | MAPK14 (0.58) | MAPK14MAPK13ABL1BRAFFGFR1 | |
| SCHEMBL3808752 | 0.83 | MAPK14 (0.60) | MAPK14MAPK13ABL1BRAFFGFR1 | |
| SCHEMBL3672519 | 0.83 | MAPK14 (0.59) | MAPK14MAPK13ABL1BRAFRAF1 | |
| SCHEMBL3797307 | 0.79 | MAPK14 (0.51) | MAPK14MAPK13ABL1BRAFFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, BRAF, RET | MAPK14 267/4885MAPK13 183/4885ABL1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.